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doi:10.1016/j.ejvs.2008.11.028Abstracts Objectives: Cilostazol improves walking distance in peripheral arterial disease
(PAD) patients. The study objectives were to assess the effects of cilostazol on walking
distance, followed by the additional assessment of cilostazol on exercise-induced ischae-
miaereperfusion injury in such patients.
Methods: PAD patients were prospectively recruited to a double-blinded, placebo-controlled
trial. Patients were randomised to receive either cilostazol 100 mg or placebo twice a day.
The primary end-point was an improvement in walking distance. Secondary end-points
included the assessment of oxygen-derived free-radical generation, antioxidant consumption
and other markers of the inflammatory cascade. Initial and absolute claudication distances
(ICDs and ACDs, respectively) were measured on a treadmill. Inflammatory response was as-
sessed before and 30 min post-exercise by measuring lipid hydroperoxide, ascorbate, a-
tocopherol, b-carotene, P-selectin, intracellular and vascular cell-adhesion molecules (I-CAM
and V-CAM), thromboxane B2 (TXB2), interleukin-6, interleukin-10, high-sensitive C-reactive
protein (hsCRP), albuminecreatinine ratio (ACR) and urinary levels of p75TNF receptor. All
tests were performed at baseline and 6 and 24 weeks.
Results: One hundred and six PAD patients (of whom 73 were males) were recruited and
successfully randomised from December 2004 to January 2006. Patients who received cilosta-
zol demonstrated a more significant improvement in the mean percentage change from base-
line in ACD (77.2% vs. 26.6% at 6 weeks, pZ 0.026 and 161.7% vs. 79.0% at 24 weeks, pZ 0.048)
as compared to the placebo. Cilostazol reduced lipid hydroperoxide levels compared to
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The Effects of Cilostazol on Exercise-induced Ischaemiaereperfusion Injury 327þ5.8%, pZ 0.003 and post-exercise: 12.3% vs. þ13.9%, pZ 0.007 and 24 weeks: pre-exercise
15.5% vs. þ12.0%, pZ 0.025 and post-exercise: 9.2% vs. þ1.9%, pZ 0.028). b-Carotene
levels were significantly increased in the cilostazol group, compared to placebo, before exer-
cise at 6 and 24 weeks (6 weeks: 34.5% vs. 7.4%, pZ 0.028; 24 weeks: 34.3% vs. 17.7%,
pZ 0.048). Cilostazol also significantly reduced P-selectin, I-CAM and V-CAM levels at 24 weeks
as compared to baseline (p< 0.05). There was no difference between treatment groups for
ascorbate, a-tocopherol, interleukin-6 and -10, hsCRP and p75TNF receptor levels.
Conclusions: Cilostazol significantly improves ACD, in addition to attenuating exercise-induced
ischaemiaereperfusion injury, in PAD patients.
ª 2008 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Intermittent claudication has been likened to ischaemia
followed by reperfusion, which usually occurs during lower
limb-revascularisation procedures, leading to an ischae-
miaereperfusion injury.1,2 This concept was first reported,
in 1960, when two patients with acutely ischaemic lower
limbs developed massive ischaemic myopathy and myoglo-
binuria after re-vascularisation.3 Following ischaemia, the
muscles may be salvaged by reperfusion. However, the re-
introduction of oxygen to hypoxic muscles can also lead to
damage by oxygen-derived free radicals (ODFR). Patients
with intermittent claudication have been reported to
demonstrate a similar exercise-induced inflammatory
response with elevation in lipid peroxide and plasma
thromboxane (TX) levels as early as 15 min following exer-
cise associated with a corresponding reduction in antioxi-
dant levels.1,2,4 Khaira et al.,4 in 1995, proposed that the
presence of ischaemiaereperfusion events in patients with
intermittent claudication leads to a systemic increase in
vascular permeability as a result of endothelial injury or
dysfunction, combined with the localised production of
inflammatory mediators, including TX, as well as neutro-
phil, activation. Although initially protective, these mech-
anisms can become excessive, resulting in damaged tissue,
impaired organ function and an abnormal fibro-proliferative
response.5
Cilostazol, a 2-oxo-quinolone derivative, is a reversible,
selective inhibitor of phosphodiesterase-3A (PDE-3A) with
antiplatelet, antithrombotic, vasodilatory, antimitogenic
and cardiogenic properties.6 Cilostazol appears to increase
intracellular cyclic adenosine monophosphate (cAMP) by
inhibiting PDE-3A whilst reducing adenosine uptake into
cells.6,7 The adenosine augments the cAMP-elevating effect
of PDE-3 inhibition in platelets and smooth muscle cells.6
Cilostazol has been shown to have possible attenuating
effects on the inflammatory cascade from review of in
vitro, animal and case-controlled human studies. Hakaim
et al. demonstrated that a cilostazol infusion 10 min before
re-vascularising an ischaemic leg prevented anterior
compartment pressure increases.8 In addition, Otsuki et al.
reported an inhibition of tumour necrosis factor-a (TNF-a)-
and vascular cell-adhesion molecule-1 (V-CAM-1)-mediated
products with cilostazol. This inhibition may be via cAMP
elevation in human vascular endothelial cells, thus pre-
venting atherosclerosis.9 Cilostazol also exerts beneficial
effects on platelet-derived growth factor, monocyte
chemo-attractant protein-1 and hepatocyte growth
factor.10 In Type-2 diabetes patients, cilostazol significantly
reduces platelet-derived microparticles, activatedplatelets and soluble adhesion molecules.11 Lee et al.
suggested that cilostazol may also reduce current and
future cardiovascular events through improvements in lipid
profiles accompanied by a reduction in interleukin-6 (IL-6)
levels.12 Therefore, it is postulated that all of these cil-
ostazol-mediated effects on the inflammatory cascade
could lead to improvements both in lower limb function and
longer-term cardiovascular outcomes.
We conducted a prospective double-blinded, rando-
mised, placebo-controlled clinical trial to assess the
hypothesis that cilostazol improves walking distances as
well as attenuates exercise-induced ischaemiaereperfusion
injury in patients with intermittent claudication.
Methods
Patient recruitment and randomisation
Male and female (non-pregnant) patients between the ages
of 30 and 90 years were eligible for recruitment to this
single-centre clinical trial between December 2004 and
January 2006. The study was approved by the local
Research Ethics (Application No.147/04) and Hospital Clin-
ical Governance Committees (BCH04059MO/L). The clinical
trial was also registered with the European Clinical Trials
Database (EUDRACT 2004-004846-42).
Patients were suitable for inclusion if they had inter-
mittent claudication, defined as reproducible muscle
discomfort in the lower limb produced by exercise and
relieved by rest, with an ankleebrachial index less than
0.9, which had been stable on optimal medical therapy that
included antiplatelet and lipid-lowering medication,
cardiovascular risk assessment and treatment (e.g.,
hypertension) and smoking-cessation therapy combined
with the provision of exercise advice for a period of
3 months.13 Although exercise advice was provided during
vascular consultations, there was no provision for accurate
monitoring of exercise compliance in the community.13
Patients were excluded if they had current or previous
acute or critical limb ischaemia,13 severe claudication that
prohibited the use of treadmill testing as determined
during pre-recruitment vascular assessments, an endovas-
cular or surgical procedure within the preceding 6 months
or a non-atherosclerotic co-morbidity that had limited their
walking before the onset of claudication pain. Exclusion
criteria also included a predisposition to bleeding, a history
of uncontrolled cardiac, respiratory, renal or liver disease
328 M.E. O’Donnell et al.or the use of omeprazole and diltiazem, as per cilostazol
safety guidelines.
A power calculation for patient numbers based on
a marker of inflammatory response as the primary outcome
measure was desired. However, during protocol design,
a suitable reference study assessing the exercise-induced
inflammatory response in patients with intermittent clau-
dication could not be identified. The power calculation for
the study was, therefore, calculated from walking-distance
indices derived from Dawson et al.14 for two separate
patient populations (normoglycaemic and diabetic).
Therefore, 30 patients per treatment group completing
the trial would have a 90% power to detect a statistically
significant (p< 0.05; two-tailed) difference in the change
in maximal walking distance, between groups, of
a magnitude of 45 m. This assumes a mean baseline
maximal walking distance of 150 m and standard deviation
of 54 m and an improvement of 30% in one group and no
change in the other.14 It was assumed that approximately
20% of patients would withdraw from the study due to an
adverse reaction to the study medication (headache,
diarrhoea or palpitations). A further 12 patients would be
recruited to a total of 72 patients for each of the nor-
moglycaemic and diabetic populations to account for
drop-outs. Therefore, a total of 144 patients were
required. Our study was performed on an intention-to-
treat principle.
The primary end-points were, therefore, improved in
initial and absolute walking distances. Secondary end-points
included the assessment of ODFR generation, antioxidant
consumption and other markers of the inflammatory
cascade, including selectins, cell-adhesion molecules, TX,
ILs and high-sensitive C-reactive protein (hsCRP).
Two baseline assessments, 4 weeks apart, facilitated
stabilisation before treatment allocation. The mean of
these two values was calculated as the baseline reading.
Following written informed consent, patients were rando-
mised into groups of four to receive cilostazol (100 mg) or
matched placebo twice a day orally. Patient-treatment
randomisation and allocation was performed independently
by the Department of Research Pharmacology in the Belfast
City Hospital. Both, the patient and the primary investi-
gator, were blinded to study-drug allocation, which was
completed using the sealed-envelope method. Follow-up
clinical assessments were performed at 6 and 24 weeks.
Study-drug un-blinding was performed at the end of the
study, following the completion of all clinical assessments
and laboratory analyses for all patients.Walking assessment
Each patient rested for 30 min before commencement of
testing using the same calibrated treadmill (Mortara Xscribe
Treadmill, Mortara Instrument, Inc., US) at a constant
speed of 2 mph (3.2 kph) and a 10% gradient with the
primary investigator (MOD).13 The distance when the onset
of claudication symptoms was recorded as the initial clau-
dication distance (ICD). The patient was advised to
continue walking until claudication pain precluded contin-
uation, which was defined as the absolute claudication
distance (ACD).Assessment of inflammatory response
All samples were collected after 30 min of rest before
exercise and at 30 min following exercise. Plasma samples
for ascorbate were centrifuged immediately. Urine was
collected for analysis of p75TNF receptors. Serum was
collected for all other assays. Serum was allowed to clot for
15 min and was then centrifuged. All samples were trans-
ferred to 2-ml tubes (Sarstedt, Ireland) and stored at
80 C. Intra- and inter-assay coefficients of variation were
within satisfactory limits according to the manufacturers’
guidelines.
Plasma lipid hydroperoxides
These were measured spectrophotometrically using the
ferrous oxidationexylenol orange version 1 assay (FOX 1).
Ascorbate
Concentrations were determined by the enzymatic oxida-
tion of ascorbic acid and subsequent quinoxaline formation.
The fluorescent derivative was measured on the Cobas Fara
centrifugal analyser with fluorescent attachment.
Lipid-soluble antioxidants e a-tocopherol and b-carotene
These levels were measured using a high-performance
liquid chromatography technique (HPLC).
P-selectin
Human serum P-selectin levels were determined using
a quantitative sandwich immunoassay technique (R&D
Systems Europe, Abingdon).
Intracellular and vascular cell-adhesion molecule and
interleukins-6 and -10
These were measured using enzyme-linked immunosorbent
assay (ELISA) kits from Eli-pair (Diaclone, Besanc¸on,
France) that were commercially available.
11-dehydro thromboxane B2 (TXB2)
TXB2 was measured using the ACE
 Competitive Enzyme
Immunoassay (EIA) and an estimate of TXA2 levels (Cayman
Chemical, MI, USA) was provided.
Urinary p75TNF receptor
This receptor was measured by using a commercially
available EASIA kit from Biosource (Nivelles, Belgium).
High-sensitive C-reactive protein (hsCRP)
This was measured using the commercially available
quantex CRP Ultra Sensitive Biokit Assay (Biokit, Barcelona,
Spain).
Statistical analysis
Descriptive statistics for patient demographics, medical co-
morbidities and examination parameters were calculated
as mean and standard error of the mean (SEM) or median
and interquartile ranges (IQR). Quantitative end-points
were analysed at the four assessment time points (4, 0, 6
and 24 weeks). ManneWhitney U (MWU) test was used to
compare differences between the cilostazol and placebo
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compare differences within one treatment group to the
baseline. All statistics were two sided and a p-value of
<0.05 was considered significant. Statistical analysis was
performed using the SPSS statistical package (Version 12,
SPSS Inc., Chicago, USA).
Results
Recruitment
A total of 561 normoglycaemic and 113 diabetic medically
fit patients, with previous optimisation of medical therapy,
were assessed for potential trial recruitment. Of these
participants, 92 normoglycaemic and 34 diabetic patients
decided not to enrol citing personal reasons, while 389 and
53 patients, respectively, did not attend the research clinic
despite the availability of multiple clinic appointments.
Therefore, 106 peripheral arterial disease (PAD) patients
(73 male) were recruited from December 2004 to January
2006 (median age: 66.5 years, range: 37e86 years).
Twenty-six patients were diabetic (Table 1). The cilostazol
and placebo treatment groups were not significantly
different with regard to baseline characteristics (Table 2).
Walking assessment
Patients who received cilostazol demonstrated a more
significant improvement in the mean percentage change
from the baseline in ACD (77.2% vs. 26.6% at 6 weeks,
pZ 0.026 and 161.7% vs. 79.0% at 24 weeks, pZ 0.048) as
compared to the placebo. A mean percentage improvement
from the baseline in ICD was also demonstrated in both the
treatment groups (38.9% vs. 22.7% at 6 weeks, pZ 0.06 and
67.0% vs. 51.6%, pZ 0.63 at 24 weeks). However, this was
not significant (Fig. 1).Table 1 Patient recruitment algorithm
RECRUITED TO
(n=80 + 26 =
Patients with peripheral a
were medically fit with p
medical trea
Personal reasons
(n=92)
Failure to attend out-patient
department
(n=389)
Normoglycaemic
(n=561)Inflammatory response
Lipid hydroperoxides
The baseline pre- and post-exercise levels were similar in
both groups. There was a significant reduction in the cil-
ostazol group before and after exercise at 6 and 24 weeks
(Table 3). A significant reduction was identified in the mean
percentage change from the baseline for the cilostazol
group as compared to an increase in the placebo group
(6 weeks: pre-exercise: 11.8% vs. þ5.8%, pZ 0.003 and
post-exercise: 12.3% vs. þ13.9%, pZ 0.007; 24 weeks:
pre-exercise 15.5% vs. þ12.0%, pZ 0.025 and post-exer-
cise: 9.2% vs. þ1.9%, pZ 0.028).
Ascorbate, corrected a-tocopherol and b-carotene
There was no difference between the cilostazol and
placebo groups at any time point (Table 3). A trend for
a higher residual ascorbate level appeared in the cilostazol
group at 24 weeks (pre-exercise: 30.0% vs. 10.0%, pZ 0.24
and post-exercise: 23.2% vs. 2.4%, pZ 0.55). b-Carotene
levels were significantly increased in the cilostazol group,
as compared to the placebo group, before exercise at 6 and
24 weeks (6 weeks: 34.5% vs. 7.4%, pZ 0.028; 24 weeks:
34.3% vs. 17.7%, pZ 0.048).
P-Selectin, intracellular cell-adhesion molecule (I-CAM),
V-CAM and 11-dehydro TXB2
There were no significant differences in P-selectin, I-CAM,
V-CAM and 11-dehydro TXB2 levels between the groups at
any time point (Table 4).
However, P-selectin levels were reduced in the cilostazol
group before and after exercise when the 24-week levels
were compared to baseline levels, with no difference seen in
the placebo group (cilostazol: pre-exercise; pZ 0.001 and
post-exercise p< 0.001) (placebo: pre-exercise pZ 0.16
and post-exercise pZ 0.18) (Fig. 2). I-CAM and V-CAM levelsPersonal reasons
(n=34)
Failure to attend out-patient
department
(n=53)
 STUDY
 106)
rterial disease who
rior optimisation of
tment  
Diabetic
(n=113)
Table 2 Baseline patient demographics, co-morbidities and walking status (median, IQR unless stated as range) (Manne
Whitney U test)
Variable Cilostazol Placebo p-Value
Number of patients 51 55 0.83
Sex MZ 34, FZ 17 MZ 39, FZ 16 0.29
Median age in years (range) 64.2 (37e86) 66.1 (39e80) 0.29
Past medical history
Hypertension 32 (62.7%) 37 (67.3%) 0.63
Hypercholesterolaemia 39 (76.5%) 42 (76.4%) 0.99
Diabetes 12 (23.5%) 14 (25.5%) 1.0
Angina 7 (13.7%) 3 (5.5%) 0.25
Myocardial infarction 9 (17.6%) 7 (12.7%) 0.46
Coronary artery bypass grafting 3 (5.9%) 5 (9.1%) 0.91
Cerebrovascular accident 3 (5.9%) 3 (5.5%) 0.78
Carotid endarterectomy 2 (3.9%) 3 (5.5%) 0.28
Abdominal aortic aneurysm 0 (0%) 1 (1.8%) 1.0
Previous vascular arterial
bypass/endovascular intervention
4 (7.8%) 6 (10.9%) 0.74
Medical therapy
Aspirin 37 44 0.94
Clopidogrel 12 8 0.65
Warfarin 2 3 0.97
Statin 48 52 0.93
ACE inhibitors 15 18 0.72
ACE II antagonists 8 4 0.18
B-blocker 9 14 0.34
Calcium antagonist 9 12 0.60
Diuretic 18 18 0.78
Walking capabilities
Limb affected LZ 8, RZ 8, BothZ 35 LZ 6, RZ 7, BothZ 42 0.72
Duration of symptoms in years 2.0 (1.0e5.5) 3.0 (1e5) 0.59
Initial claudication distance (metres) 69.7 (50.1e94.8) 63.9 (45.2e85.8) 0.67
Absolute claudication distance (metres) 144.4 (99.7e204.3) 138.6 (101.7e193.8) 0.44
Index limb ABI 0.77 (0.65e0.89) 0.74 (0.52e0.88) 0.10
Smoking history
Smoking status
Non-smoker 5 3 0.43
Ex-smoker 23 22
Current smoker 23 30
Packs cigarettes/day 1 (1e1.63) 1 (0.75e2.25) 0.49
Smoking duration (years) 40 (32.5e50) 40 (20e55) 0.11
Pack years 42 (33e63) 40 (20e50) 0.50
330 M.E. O’Donnell et al.were reduced in the cilostazol group before exercise and in
the I-CAM levels after exercisewhen the 24-week levels were
compared to baseline levels, with no difference in the
placebo group (cilostazol pre-exercise: I-CAM pZ 0.003 and
V-CAM pZ 0.016 and post-exercise: I-CAM pZ 0.04 and V-
CAM pZ 0.16). There was a reducing trend in the cilostazol
group at 6 weeks when the mean percentage change in 11-
dehydro TXB2 levels was compared to the baseline.
Interleukin-6, interleukin-10, p75TNF receptor and hsCRP
There was no significant difference between the cilostazol
and placebo groups at any time point (Table 5). However,
a clear disparity in the IL levels between the treatment
groups was demonstrated, due to a large number of
equivocal or sub-threshold readings.Albuminecreatinine ratio (ACR)
The baseline pre- and post-exercise ratios were similar
between the studygroups. Therewas a significant reduction in
theACRbefore andafter exercise at 6weeks (0.70 mgmg1 vs.
1.35 mgmg1, pZ 0.039 and 1.30 mgmg1 vs. 2.70 mgmg1,
pZ 0.043) and before exercise at 24 weeks (0.60 mgmg1 vs.
1.50 mgmg1, pZ 0.017) when the cilostazol group was
compared to the placebo group (Table 5).Study completion
A total of 91 patients completed the clinical trial. This
included 15 patients who failed to complete the study,
which corresponded to a 14.2% drop-out rate (cilostazol: 8
Figure 1 Mean percentage change from baseline in initial and absolute walking distances at 6 and 24 weeks (Mean, SEM) (Manne
Whitney U test).
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cilostazol group, six patients withdrew because of side
effects, one patient was non-compliant with treatment
after the 6th-week assessment point and one patient had
a serious adverse event unrelated to the cilostazol treat-
ment due to a gastrointestinal bleed secondary to an
increased consumption of alcohol whilst on holiday after 23
weeks in the study. In the placebo group, two patients
withdrew due to side effects, two patients were withdrawn
after the 6th-week assessment by the primary investigator
due to the onset of critical ischaemia, two patients were
non-compliant with treatment after the 6th-week assess-
ment point and one patient had a serious adverse event
secondary to the addition of two additional antihyperten-
sive agents, which resulted in acute renal failure that
settled with conservative management. Following comple-
tion of the clinical trial, patients were continued on cil-
ostazol therapy, if appropriate, or commenced on cilostazol
if they had been prescribed the placebo treatment. All
patients were subsequently reviewed in the routine
vascular outpatient clinic thereafter as ethical approval
only facilitated inclusion of study assessments at the 6- and
24-week time points.
Discussion
Ischaemiaereperfusion injury can occur in patients with
lower limb ischaemia during walking and resting and after
arterial bypass surgery.1 Elevations in lipid peroxide and
plasma TX levels have been shown to occur 15 min following
exercise that is associated with a corresponding reduction
in antioxidant levels.1,4 Khaira et al. 4 demonstrated that
this ischaemiaereperfusion injury leads to a systemic
increase in vascular permeability due to endothelial injury
combined with localised production of pro-inflammatory
mediators.
This study demonstrated lower lipid hydroperoxide
levels in the cilostazol group, compared to an actual mean
percentage increase from the baseline in the placebo
group. This reduction was identified at 6 weeks andcontinued to be present until the 24th-week assessment,
similar to other reports.15 In contrast to this study, all other
studies were performed on animal models or in in vitro
laboratory-based human cell lines. These lipid hydroper-
oxide changes may be related to a cilostazol-mediated
improvement in lipid homeostasis, since modified low-
density lipoprotein (LDL) is fundamental to the process of
lipid peroxidation.12 Although it is unclear why the placebo
group demonstrated an increase in lipid hydroperoxide
levels, possible reasons include an increase in oxidative
stress secondary to an increase in walking distance (26.6%
at 6 weeks and 79% at 24 weeks). These effects in the
placebo group also demonstrate that exercise does lead to
activation of the inflammatory cascade via free-radical
generation. However, the longer-term consequences of an
exercise-induced inflammatory response in claudicating
patients require further study, but our data demonstrate
that cilostazol may have an important therapeutic role.
The oxidative damage associated with ODFR may also
lead to the consumption of endogenous antioxidants, such
as ascorbate and a-tocopherol, which act as ODFR scaven-
gers to prevent oxidation of proteins and lipids.16 PAD
patients have lower baseline vitamin C concentrations,
especially those with a low ACD. A low concentration of
vitamin E has also been shown to correlate with maximal
lipid peroxidation after lower limb arterial bypass.16 The
oral administration of vitamins C and E reduces exercise-
induced oxidative injury and interferes with the expression
of other inflammatory mediators such as selectins and
I-CAM.17 The lack of significance in ascorbate concentra-
tions in this study may be due to these antioxidants
requiring a longer duration of therapy before any notice-
able change occurs. This could explain the minimal
percentage change detected at 6 weeks, while an increase
in the cilostazol group was detected at 24 weeks.
Other researchers have reported that the resistance of
LDLs to oxidation may not actually correlate with vitamin E
content and that other lipid-soluble antioxidants, such as
ubiquinol-10, may be a more important first-line antioxi-
dant.18 The changes in all of these antioxidants may not be
Table 3 Lipid hydroperoxides and antioxidant levels before and after exercise at baseline, 6 and 24 weeks (median, IQR) (ManneWhitney - U test)
Parameter Assessment Pre-exercise Post-exercise
Cilostazol Placebo p-Value Cilostazol Placebo p-Value
Lipid hydroperoxide (nmol/l) Baseline 0.55 (0.36e0.81) 0.63 (0.43e0.95) 0.26 0.61 (0.34e0.79) 0.64 (0.46e0.89) 0.27
6 Weeks 0.46 (0.33e0.61) 0.64 (0.47e0.85) 0.001 0.49 (0.37e0.60) 0.68 (0.53e0.86) <0.001
24 Weeks 0.45 (0.33e0.61) 0.61 (0.46e0.82) 0.001 0.46 (0.32e0.61) 0.62 (0.51e0.88) 0.005
Ascorbate (mmol/l) Baseline 20.5 (10.2e42.0) 28.6 (11.4e42.3) 0.63 22.7 (9.5e42.8) 30.2 (14.3-47.4) 0.54
6 Weeks 14.2 (3.2e40.9) 23.0 (5.5e35.8) 0.54 16.1 (5.3e47.7) 26.1 (12.4e41.3) 0.37
24 Weeks 24.8 (3.2e42.1) 24.2 (5.6e45.4) 0.85 27.4 (4.5e43.7) 27.2 (6.5e49.1) 0.63
Corrected a-tocopherol (mmol/l) Baseline 6.77 (5.55e8.13) 6.43 (5.76e7.25) 0.35 6.46 (5.38e7.91) 6.43 (5.72e7.34) 0.69
6 Weeks 6.11 (5.50e7.56) 6.41 (5.84e7.28) 0.89 6.06 (5.30e7.46) 6.29 (5.70e6.98) 0.66
24 Weeks 6.35 (5.52e7.83) 6.92 (6.05e7.89) 0.28 6.79 (5.54e7.99) 6.99 (6.33e8.05) 0.36
b-Carotene (mmol/l) Baseline 0.20 (0.13e0.29) 0.21 (0.13e0.32) 0.88 0.20 (0.12e0.28) 0.21 (0.12e0.33) 0.81
6 Weeks 0.21 (0.12e0.38) 0.19 (0.08e0.31) 0.26 0.21 (0.14e0.38) 0.19 (0.10e0.29) 0.25
24 Weeks 0.25 (0.14e0.41) 0.21 (0.09e0.33) 0.35 0.28 (0.11e0.38) 0.19 (0.11e0.35) 0.26
Table 4 Selectins and cell-adhesion-molecule levels before and after exercise at baseline, 6 and 24 weeks (median, IQR) (ManneWhitney - U test)
Parameter Assessment Pre-exercise Post-exercise
Cilostazol Placebo p-Value Cilostazol Placebo p-Value
P-selectin (ng/ml) Baseline 97.8 (74.4e119.8) 88.4 (73.1e109.5) 0.27 95.1 (67.7e124.5) 90.6 (70.9e110.5) 0.50
6 Weeks 96.9 (79.7e113.8) 88.3 (75.4e105.0) 0.20 99.9 (73.7e123.3) 90.3 (73.7e109.5) 0.27
24 Weeks 94.0 (69.8e116.5) 88.6 (70.8e102.0) 0.51 90.5 (69.8e113.0) 85.5 (67.8e104.0) 0.63
Intracellular cell-adhesion-
molecule (ng/ml)
Baseline 841.0 (711.8e1040.8) 858.0 (674.5e970.5) 0.68 841.0 (722.5e1055.5) 853.0 (722.5e1011.5) 0.78
6 Weeks 815.5 (703.5e1079.5) 866.0 (698.5e1008.3) 0.84 871.5 (712.0e1073.5) 893.0 (705.3e1052.5) 0.94
24 Weeks 818.5 (649.5e961.8) 807.0 (681.5e957.0) 0.82 829.0 (681.5e1020.0) 837.0 (693.0-1019.0) 0.91
Vascular cell-adhesion-
molecule (ng/ml)
Baseline 903.5 (788.0e1110.8) 1027.0 (782.5e1155.0) 0.58 935.5 (806.0e1153.0) 1020.0 (811.5e1142.5) 0.66
6-weeks 921.5 (789.0e1079.5) 949.5 (810.8e1135.0) 0.47 877.0 (795.5e1106.8) 979.0 (831.5e1118.5) 0.24
24-weeks 881.5 (762.0e1046.3) 989.0 (777.0e1097.0) 0.36 919.0 (783.5e1050.5) 1002.0 (811.5e1157.0) 0.18
Thromboxane B2 (pg/ml) Baseline 864.6 (342.6e1612.9) 744.9 (509.5e2288.1) 0.74 722.8 (408.1e1228.4) 953.9 (458.6e1959.6) 0.19
6 Weeks 580.2 (344.5e1410.7) 886.1 (465.6e2026.6) 0.16 564.1 (332.5e1423.1) 1194.8 (493.2e2134.2) 0.065
24 Weeks 637.0 (431.9e1578.6) 787.8 (377.8e1663.6) 0.63 801.0 (444.9e1697.4) 942.0 (393.6e1971.7) 0.60
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Figure 2 Mean percentage change from baseline in P-selectin levels (Mean, SEM) (Wilcoxon signed-rank test).
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more severely affected patients undergoing operative
intervention.16 Although cilostazol has no definite effect on
other antioxidants in PAD patients, our results show an
increased level of b-carotene, possibly from a relative
sparing of this antioxidant, due to a reduction in lipid
hydroperoxide levels (ODFR activity). Although the
evidence is tenuous, it may explain the changes observed in
the vitamin C concentrations.
In addition to direct cell-wall lipid peroxidation, ODFR
can cause damage indirectly by activating platelets and
leucocytes. These effects may be mediated via the selec-
tins and cell-adhesion molecules, which affect both plate-
lets and leucocytes, whilst propagating the inflammatory
celleendothelial interaction.19,20 The reduction in P-
selectin levels in the cilostazol group at 24 weeks as
compared to the baseline is similar to the results of Jagroop
et al. who reported reduced levels in PAD patients who
were using combination antiplatelet (aspirin and clopidog-
rel) therapy.21 A similar effect was reported in an in vitro
model where cilostazol inhibited both platelet aggregation
and P-selectin release.22 Cilostazol also reduced cell-
adhesion-molecule levels, which are important factors in
atherosclerotic lesions as they facilitate leucocyte attach-
ment to the endothelium, accounting for an increased risk
of cardiovascular disease.23
Similarly, a longer treatment duration may be necessary
to demonstrate the beneficial effects of cilostazol on the
adhesion molecules. The TXA2 is an important stimulant of
platelet aggregation and vasoconstriction and acts as
a powerful chemo-attractant for further neutrophil acti-
vation during ischaemiaereperfusion injury.24 The TXA2
effects on neutrophils and platelets is mediated through
multiple factors, including I-CAM-1.25 This study, however,
found no difference between groups with regards to TXB2,
an index commonly used to estimate TXA2 levels.
Elevated levels of IL-6 and TNF-a production have been
reported following ischaemiaereperfusion injury.26 Lee
et al. have previously demonstrated that 8 weeks of cil-
ostazol therapy in patients with intermittent claudication
significantly reduced IL-6 levels with correlation toimproved triglyceride and high-density lipoprotein
profiles.12 However, this study had only 16 patients per
treatment limb. Contrary to these findings, our study did
not demonstrate such a response or difference between
treatment groups for IL-6 levels. As the detection of
circulating, free-TNF-a is unpredictable due to its short
half-life and sporadic release, we measured soluble TNF
receptors (p75TNF-R), which are more stable with a longer
half-life. Edrees et al. reported increased urinary p55TNF-R
in patients with intermittent claudication and critical limb
ischaemia undergoing lower limb arterial bypass.27 Like
IL-6, we found no difference in p75TNF receptor levels
between treatment groups.
However, there were limitations regarding our IL anal-
yses. During lower limb arterial bypass, IL-6 concentrations
have been shown to peak between 12 and 24 h after de-
clamping, with a subsequent rapid return to normal values.
Therefore, our 30-min post-exercise sampling time frame
may not detect this peak IL-6 response and may account for
a large amount of our samples recording a 0 pg ml1 value.
Previous perioperative aortic aneurysm and lower limb
studies from our unit have used wider sampling windows
ranging from the immediate post-operative period to 48 h
following the primary surgery.27 These assessment points
were not possible in our study as patients were only
assessed in the outpatient department. The detection limit
of 6.25 pg ml1 for the assays used in this study may not
have been sufficiently sensitive and, thus, any value below
this threshold was recorded as 0 pgml1. The use of a high-
sensitivity IL-6 ELISA would be optimal, with detection
limits of 0.2 pg ml1.12 Blood sampling from a remote site,
such as the antecubital fossa, may have missed the local-
ised cytokine burst due to systemic circulatory dilution.
Furthermore, the volume of tissue affected by ischaemiae
reperfusion injury is small in claudication, affecting only
the calf in most patients as compared to multiple organs
being affected after aortic surgery.
Ischaemiaereperfusion injury can lead to local and
remote organ damage, such as an increase in glomerular
permeability and trans-capillary leak of plasma proteins,
which subsequently results in an increase in renal albumin
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334 M.E. O’Donnell et al.excretion.28 This increased urinary ACR occurs in patients
with claudication following treadmill exercise.1,28 Hickey
et al.28 suggested that such increases in urinary ACR relate
to the degree of muscle ischaemia and that this increase is
reduced following successful lower limb arterial bypass.
Our results imply that cilostazol may exert this reno-
protective role through the reduction in ODFR generation.
CRP is emerging as a predictor of future cardiovascular
events and is associated with PAD.29 Contrary to studies by
Tisi et al., who reported a reduction in CRP in claudicants in
a supervised exercise program, we did not demonstrate any
difference between the cilostazol and placebo groups.30
However, their study was conducted over a longer period of
time, which suggests that a further period of time may be
required to elicit this effect in patients with intermittent
claudication. In addition, cilostazol may not ameliorate
CRP levels in patients with mild-to-moderate PAD.
In conclusion, cilostazol significantly attenuates an
exercise-induced host-inflammatory response in patients
with PAD with significant improvements in levels of lipid
hydroperoxides, b-carotene, P-selectin and cell-adhesion
molecules. Although the mechanism of action for cilostazol
remains unclear, free-radical generation and antioxidant
consumption are key pathways for the modulation of host-
inflammatory response in patients with intermittent claudi-
cation. The role of cytokines remains unresolved. The short
post-exercise sampling from a remote venous site may have
led to undetectable concentrations. The lack of significance
in some of the parameters may also be due to the cilostazol
group walking further and thus suffering the same degree of
ischaemiaereperfusion injury as the placebo group.
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